People: Synageva BioPharma Corp (GEVA.O)

GEVA.O on Nasdaq

4 Mar 2015
Change (% chg)

$0.57 (+0.56%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Search Stocks

Malley, Thomas 

Brief Biography

Mr. Thomas R. Malley is Independent Director of Synageva Biopharma Corp since November 2, 2011. prior to that time served as a director of Private Synageva since October 2006. Since May 2007, Mr. Malley has served as President of Mossrock Capital, LLC, a private investment firm. From December 1998 to May 2007, Mr. Malley served with Janus Mutual Funds, including as Vice President and Portfolio Manager for the Janus Global Life Sciences Fund. From April 1991 to December 1998, Mr. Malley served as an equity analyst for Janus Mutual Funds. Mr. Malley previously served as a director of Cougar Biotechnology, Inc. from 2007 to 2009, which was a publicly traded company until Johnson & Johnson acquired the company in 2009. Mr. Malley also previously served as a director of Craig Hospital, a non-profit hospital, from 2007 to 2013 and St. Anthony Hospital, a non-profit hospital, from 2004-2009. Mr. Malley is also a director of Puma Biotechnology, Inc. and OvaScience, Inc. two publicly traded biotechnology companies, and is also a director of Project Cure, a non-profit organization. Mr. Malley holds a B.S. in Biology from Stanford University. Mr. Malley’s industry and investment experience benefits the Board of Directors.

Basic Compensation

Total Annual Compensation, Long-Term Incentive Plans, All Other, Fiscal Year Total,
-- -- -- --

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Felix Baker


Sanj Patel


Carsten Boess


Robert Bazemore


Anthony Quinn


Ulrich Goldmann

As Of 30 Dec 2013
Search Stocks